Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Resverlogix Corp.
  6. Summary
    RVX   CA76128M1086

RESVERLOGIX CORP.

(RVX)
  Report
Delayed Quote. Delayed Toronto Stock Exchange - 01/17 12:37:34 pm
0.52 CAD   -1.89%
2021RESVERLOGIX : The Future of Drug Development, CEO Clip Video
NE
2021Resverlogix Announces Corporate Update Webcast and Conference Call
AQ
2021RESVERLOGIX : Md&a q3 2021
PU
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
01/11/2022 01/12/2022 01/13/2022 01/14/2022 01/17/2022 Date
0.5(c) 0.51(c) 0.53(c) 0.53(c) 0.52(c) Last
4 185 50 832 40 065 18 023 7 014 Volume
0.00% +2.00% +3.92% 0.00% -1.89% Change
More quotes
Estimated financial data (e)
Sales 2019 - - -
Net income 2019 -163 M - -
Net Debt 2019 144 M - -
P/E ratio 2019 -1,41x
Yield 2019 -
Sales 2020 - - -
Net income 2020 2,46 M - -
Net Debt 2020 39,5 M - -
P/E ratio 2020 84,0x
Yield 2020 -
Capitalization 101 M 101 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 39,3%
More Financials
Company
Resverlogix Corp. is a Canada-based clinical biotechnology company that is focused on improving the lives of patients with chronic illnesses. The Company is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the... 
More about the company
All news about RESVERLOGIX CORP.
2021RESVERLOGIX : The Future of Drug Development, CEO Clip Video
NE
2021Resverlogix Announces Corporate Update Webcast and Conference Call
AQ
2021RESVERLOGIX : Md&a q3 2021
PU
2021RESVERLOGIX : Financial Statement Q3 2021
PU
2021Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021Resverlogix Enters into a Cooperation Agreement with Supreme Council of Arab-African Ec..
MT
2021Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-Af..
AQ
2021Resverlogix in Active Talks With Morocco's Ministry of Health to Launch COVID-19 Clinic..
MT
2021Resverlogix In Active Discussions With The Kingdom of Morocco's Ministry of Health For ..
AQ
2021Resverlogix Corp. in Active Discussions with Kingdom of Morocco?s Ministry of Health fo..
CI
2021Resverlogix to Participate in Leading Scientific Conferences
AQ
2021RESVERLOGIX : Study demonstrates resverlogix's apabetalone treatment significantly improve..
AQ
2021RESVERLOGIX : to Present at Upcoming Conferences
AQ
2021RESVERLOGIX : Receives Ethics Board Approval to Begin a Clinical Study for Apabetalone as ..
MT
2021RESVERLOGIX : Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical..
GL
More news
News in other languages on RESVERLOGIX CORP.
2021Resverlogix et Eversana s'associent pour soutenir la commercialisation initiale de l'ap..
2021Resverlogix conclut un accord de financement par obligations de 6 millions de dollars U..
2021Resverlogix affirme que l'apabétalone est une première médicale chez les patients attei..
2021Resverlogix affirme que le traitement à l'apabétalone prévient l'infection des cellules..
2021Resverlogix en hausse de 3 % grâce aux preuves publiées des effets bénéfiques de l'apab..
More news
Chart RESVERLOGIX CORP.
Duration : Period :
Resverlogix Corp. Technical Analysis Chart | RVX | CA76128M1086 | MarketScreener
Technical analysis trends RESVERLOGIX CORP.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Managers and Directors
Donald J. McCaffrey Chairman, President, CEO & Secretary
Anthony Brad Cann Chief Financial Officer
Norman C. W. Wong Chief Scientific Officer
Jan O. Johansson Senior Vice President-Medical Affairs
Michael T. Sweeney Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
RESVERLOGIX CORP.1.96%101
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338